Cannabis Industry Outlook 2027|Policy & Law|Germany|12 min read

Germany’s pilot markets will decide Europe’s next five years

Drug policy researcher Dr. Miriam Keller has studied cannabis regulation in eleven European countries. Her three predictions for 2027, and why she believes the continent is watching Berlin.

Portrait 16:10
Dr. Miriam Keller in Berlin.

Three predictions for 2027

By Dr. Miriam Keller

  1. Germany’s regional pilot markets will produce the first reliable European sales data.For the first time, regulators will have evidence on pricing, potency and the illicit market rather than estimates.
  2. At least two more EU countries will announce pilot programmes of their own.Most will copy Germany’s model of limited, closely monitored regional trials instead of full legalisation.
  3. The debate will shift from “whether” to “how strictly.”Advertising limits, potency caps and THC labelling will become the main battlegrounds.

Few people have watched European cannabis policy as closely as Dr. Miriam Keller. Over the past fifteen years she has advised parliaments, interviewed regulators and tracked every reform from Malta to the Netherlands. We spoke with her in Berlin about what 2027 will bring.

This interview has been edited for length and clarity.

The pilot markets

Why do you think Germany’s pilot markets matter so much?

Miriam Keller:Because Europe has never had good data. Every debate so far has relied on assumptions about what would happen if adults could buy cannabis legally. The German pilots are designed to measure it: who buys, how much, at what price and whether the illicit market actually shrinks.

By the end of 2027 we will have a full year of numbers. That changes the conversation in every capital, not only in Berlin.

“Europe has argued about cannabis for decades without evidence. 2027 is the year the evidence arrives.”
Dr. Miriam Keller

Europe’s patchwork

Will other countries follow Germany’s approach?

Miriam Keller:Some will, but carefully. Governments like the idea of a time-limited trial because it can be stopped if the results are bad. I expect at least two more announcements next year, most likely from countries that already allow medical cannabis and have a regulator ready to run it.

What we will not see is a single European model. Each country will move at its own pace, and that patchwork will be the defining feature of the next five years.

What could go wrong

What is the biggest risk to your predictions?

Miriam Keller:Politics. A change of government can pause a pilot overnight. The data will only matter if the programmes survive long enough to produce it, so the next election cycle is the variable I watch most closely.

This prediction supports Key Theme 01Evidence replaces argument
→

Disclosure

Shareholdings
None in cannabis companies.
Advisory roles
Unpaid adviser to a parliamentary working group on drug policy.
Paid relationships
None.

The views expressed are the expert’s own. Content is for information only and does not constitute investment, legal or medical advice. See our methodology. The expert and interview on this page are sample content for a design prototype.

Get in touch.

For expert nominations, interview requests, partnerships and press enquiries.

contact@example.com →

We reply within three business days.